Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Refractory Peripheral T-cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01116154
What this trial is testing

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+28 more
City of Hope Medical Center 30
Testing effectiveness (Phase 2)UnknownNCT04279379
What this trial is testing

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Who this might be right for
Extranodal NK/T-cell Lymphoma
Beijing Tongren Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Early research (Phase 1)UnknownNCT04712864
What this trial is testing

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Who this might be right for
T-Cell LymphomaPeripheral T-Cell Lymphoma RefractoryCutaneous T-Cell Lymphoma Refractory+2 more
Legend Biotech USA Inc 50
Early research (Phase 1)Study completedNCT00293488
What this trial is testing

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

Who this might be right for
Lymphoma
Progen Pharmaceuticals 20
Testing effectiveness (Phase 2)Ended earlyNCT05883449
What this trial is testing

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
Affimed GmbH 25
Early research (Phase 1)Study completedNCT00073944
What this trial is testing

BCX-1777 in Treating Patients With Refractory Cancer

Who this might be right for
Cancer
BioCryst Pharmaceuticals
Not applicableNo Longer AvailableNCT05131438
What this trial is testing

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

Who this might be right for
Extranodal NK/T-cell Lymphoma
EQRx International, Inc.
Not applicableWithdrawnNCT00898612
What this trial is testing

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

Who this might be right for
Lymphoma
Mayo Clinic
Testing effectiveness (Phase 2)Looking for participantsNCT06519526
What this trial is testing

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Who this might be right for
Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University 25
Testing effectiveness (Phase 2)Looking for participantsNCT04083495
What this trial is testing

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT03141203
What this trial is testing

Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients

Who this might be right for
Peripheral T Cell Lymphoma
University of Birmingham 50
Testing effectiveness (Phase 2)Ended earlyNCT04217317
What this trial is testing

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed T-Cell LymphomaRefractory T-Cell LymphomaNon Hodgkin Lymphoma
Wake Forest University Health Sciences 6
Early research (Phase 1)Ended earlyNCT00725062
What this trial is testing

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Masonic Cancer Center, University of Minnesota 3
Testing effectiveness (Phase 2)Study completedNCT00939770
What this trial is testing

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Who this might be right for
Recurrent Childhood Anaplastic Large Cell LymphomaRecurrent Malignant Solid NeoplasmRecurrent Neuroblastoma+3 more
Children's Oncology Group 122
Early research (Phase 1)Ended earlyNCT05083208
What this trial is testing

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma
Henan Cancer Hospital 12
Testing effectiveness (Phase 2)WithdrawnNCT03586024
What this trial is testing

Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

Who this might be right for
Lymphoma
Abramson Cancer Center at Penn Medicine
Not applicableStudy completedNCT00856388
What this trial is testing

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+97 more
Roswell Park Cancer Institute 62
Testing effectiveness (Phase 2)Ended earlyNCT01637090
What this trial is testing

Everolimus in Treating Cutaneous T-cell Lymphoma

Who this might be right for
Cutaneous T-Cell Lymphoma
Adam Lerner 3
Very early researchNot Yet RecruitingNCT07213882
What this trial is testing

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Who this might be right for
Cutaneous T Cell Lymphoma (CTCL)Mycosis FungoidesSezary Syndrome
Assistance Publique - Hôpitaux de Paris 30
Next Page